Nutriband Inc
NTRBW1.700
+0.030+1.80%
Market hours （ET）Quotes delayed by 15 min
--Market Cap
--P/E TTM
More Details of Nutriband Inc Company
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Company Info
Ticker SymbolNTRBW
Company nameNutriband Inc
IPO dateJun 20, 2017
CEOMr. Gareth Sheridan
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address121 S Orange Ave Ste 1500
CityORLANDO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code32801-3241
Phone14073776695
Websitehttps://nutriband.com/
Ticker SymbolNTRBW
IPO dateJun 20, 2017
CEOMr. Gareth Sheridan
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Sergei Glinka
Mr. Sergei Glinka
Independent Director
Independent Director
--
--
Mr. Gerald Goodman
Mr. Gerald Goodman
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Alan Smith, Ph.D.
Dr. Alan Smith, Ph.D.
Chief Operating Officer, President of 4P Therapeutics
Chief Operating Officer, President of 4P Therapeutics
--
--
Mr. Radu Bujoreanu
Mr. Radu Bujoreanu
Independent Director
Independent Director
--
--
Prof. Dr. Stefani C. Mancas
Prof. Dr. Stefani C. Mancas
Independent Director
Independent Director
--
--
Ms. Irina Gram
Ms. Irina Gram
Independent Director
Independent Director
--
--
Mr. Gareth Sheridan
Mr. Gareth Sheridan
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
--
--
Mr. Mark Hamilton
Mr. Mark Hamilton
Independent Director
Independent Director
--
--
Mr. Serguei Melnik
Mr. Serguei Melnik
Chairman of the Board, President, Secretary
Chairman of the Board, President, Secretary
--
--
Dr. Jeff Patrick, Pharm.D.
Dr. Jeff Patrick, Pharm.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Sergei Glinka
Mr. Sergei Glinka
Independent Director
Independent Director
--
--
Mr. Gerald Goodman
Mr. Gerald Goodman
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Alan Smith, Ph.D.
Dr. Alan Smith, Ph.D.
Chief Operating Officer, President of 4P Therapeutics
Chief Operating Officer, President of 4P Therapeutics
--
--
Mr. Radu Bujoreanu
Mr. Radu Bujoreanu
Independent Director
Independent Director
--
--
Prof. Dr. Stefani C. Mancas
Prof. Dr. Stefani C. Mancas
Independent Director
Independent Director
--
--
Ms. Irina Gram
Ms. Irina Gram
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Feb 23
Updated: Sun, Feb 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
5
205.13K
0.00%
+64.07K
2025Q1
5
205.13K
0.00%
+64.07K
2024Q4
5
140.96K
0.00%
+9.09K
2024Q3
5
131.77K
0.00%
+162.00
2024Q2
6
201.49K
0.00%
-3.06K
2024Q1
6
197.82K
0.00%
+95.55K
2023Q4
5
95.55K
0.00%
-13.13K
2023Q3
5
101.46K
0.00%
+6.05K
2023Q2
5
88.78K
0.00%
+11.98K
2023Q1
4
70.18K
0.00%
-6.46K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Citadel Advisors LLC
152.72K
0%
+26.32K
+20.83%
Mar 31, 2025
Virtu Americas LLC
--
0%
-10.94K
-100.00%
Mar 31, 2025
Clear Street LLC
50.04K
0%
+46.63K
+1368.19%
Mar 31, 2025
UBS Financial Services, Inc.
2.37K
0%
+2.16K
+1004.19%
Mar 31, 2025
BofA Global Research (US)
--
0%
-100.00
-100.00%
Dec 31, 2023
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
